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Prognostic Value of E/E= Ratio in Patients With
Unoperated Severe Aortic Stenosis
Simon Biner, MD,*† Asim M. Rafique, MD,* Pavel Goykhman, MD,*
Ryan P. Morrissey, MD,* Jesse Naghi, MD,* Robert J. Siegel, MD*
Los Angeles, California; and Tel Aviv, Israel
O B J E C T I V E S The aim of this study was to evaluate the value of clinical and echo-Doppler
parameters for the prognosis of unoperated severe aortic stenosis (AS).
B A C KG ROUND Approximately one-third of severe, symptomatic AS patients are denied surgery.
Risk stratiﬁcation of unoperated AS is important to determine eligibility for percutaneous aortic valve
replacement, an evolving treatment option for AS patients deemed suboptimal for surgical aortic valve
replacement.
METHOD S We retrospectively compared clinical and echo-Doppler parameters between survivors
and nonsurvivors of 125 patients with unoperated severe AS.
R E S U L T S The 1-year survival rate was 62.4%. In univariate analysis, survivors compared with
nonsurvivors were younger (80.0  10.9 years vs. 84.9  11.1 years, p  0.02), had a greater left
ventricular ejection fraction (LVEF) (55  15% vs. 50  16%, p  0.042), a higher left ventricular stroke
volume (63  19 ml vs. 56  13 ml, p  0.015), a lower E/E= ratio (12.19  5.7 vs. 16.87  7.43, p 
0.001), and a lower prevalence of E/E= 15 (20% vs. 55%, p  0.001). Symptomatic status was
nonsigniﬁcantly different between survivors and nonsurvivors. In patients with an LVEF 50%, the
subgroup with E/E=15 and with E/E=15 had a 73.8% and 47.8% 1-year survival rate, respectively (p
0.027). In the patients with an LVEF 50%, the patients with E/E= 15 and those with E/E= 15
demonstrated a 70.6% and 22.3% 1-year survival rate, respectively (p  0.003). In multivariate analysis,
signiﬁcant predictors of mortality were E/E= 15 and a combination of E/E= 15 and B-type natriuretic
peptide 300 ng/ml: adjusted mortality risk 2.34 (95% conﬁdence interval (CI) 1.27 to 4.33, p  0.0072)
and 2.59 (95% CI 1.21 to 5.55, p  0.014), respectively.
CONC L U S I O N S The E/E= ratio is the single most predictive clinical and echo-Doppler parameter
in the assessment of overall prognosis in patients with unoperated severe AS. LVEF was a signiﬁcant
predictor of survival only in the univariate analysis. B-type natriuretic peptide alone was not a predictor
of prognosis in the study population. However, the combination of E/E= and B-type natriuretic peptide
is even more predictive of the 1-year prognosis. (J Am Coll Cardiol Img 2010;3:899–907) © 2010 by the
American College of Cardiology Foundation
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900ortic stenosis (AS) is the most common val-
vular heart disease in the Western world, and
its prevalence is increasing as the popula-
tion ages (1). Surgical aortic valve re-
lacement (AVR) is the only effective treatment for
evere AS in patients with symptoms or left ven-
ricular (LV) systolic dysfunction. However, in
symptomatic patients with severe AS, the timing
f surgery is controversial (2). Although a number
f centers perform AVR in selected asymptomatic
atients (3–5), the EuroHeart survey found that
ne third of symptomatic elderly patients with
evere AS were denied surgery (6). Advanced age,
omorbidities, and a reduced LV ejection fraction
LVEF) are important factors in decision making
ecause they are associated with an increased oper-
tive risk (7–13). As a result, symptomatic, mostly
lderly and debilitated AS patients receive only
edical treatment, and the prognosis of patients
ith unoperated symptomatic AS is very poor
14–21). There is likely to be a patient selection
bias for surgery among both symptomatic
and asymptomatic patients with severe
AS, with patients having the most signif-
icant comorbidities not being offered sur-
gery (4,22).
Risk assessment in unoperated AS pa-
tients, both symptomatic and asymptom-
atic, may be challenging. In elderly AS
patients with comorbidities, symptoms
may not be identified due to limited phys-
ical activity (23–28). Furthermore, the
clinical manifestations of other noncardiac
isorders (e.g., pulmonary disease, obesity, decon-
itioning) may overlap with symptoms of AS (29),
hus making it complicated to identify the primary
ause of symptoms. Risk stratification is becoming
ore important as percutaneous AVR is evolving as
treatment option for patients with severe AS with
omorbidities that may preclude surgical AVR.
The objective of our study was to evaluate retro-
pectively the impact of a spectrum of clinical and
cho-Doppler parameters on the outcomes of un-
perated patients with severe aortic valve stenosis in
he absence other significant valvular heart disease.
E T H O D S
atient selection. This was a retrospective, observa-
ional cohort study from a large community-based
edical center. The study was approved by the
ent
ionnstitutional review board. Waiver for patient con- rent was granted because of the retrospective nature
f the study.
The Cedars-Sinai Medical Center echocardiog-
aphy database was searched for patients with severe
S for the period September 2003 to May 2008.
evere AS was defined as a maximal transaortic
elocity of 4 m/s, mean transaortic pressure gra-
ient of 40 mm Hg, or aortic valve area of 1.0
m2. By reviewing medical records, we identified
46 consecutive patients with symptomatic severe
S, severe AS with LV systolic dysfunction (LVEF
50%), or asymptomatic severe AS with preserved
V systolic function (LVEF 50%) with available
ollow-up information confirming that these pa-
ients did not receive surgery. To have a study
opulation in which aortic valve stenosis was the
rimary valve lesion, 12 patients with severe mitral
egurgitation were excluded. In addition, to be able
o accurately assess LV diastolic function, 2 patients
ith mitral stenosis and 3 patients with a history of
itral valve surgery were excluded. Finally, 4 par-
icipants were excluded due to active malignancy
ith an estimated survival of 1 year. The remain-
ng 125 patients were included in the final analysis.
linical data. Clinical data included age, sex, symp-
omatic status (dyspnea, chest pain, and syncope),
istory of smoking, diabetes mellitus (patients tak-
ng antihyperglycemic medications or with a fasting
lood glucose level 125 mg/dl), hypertension
patients taking antihypertensive medications or
ith known hypertension regardless of treatment),
ypercholesterolemia (participants taking lipid-
owering medications or with a plasma low-density
ipoprotein cholesterol level 160 mg/dl), conges-
ive heart failure, atrial fibrillation, history of coro-
ary heart disease (old myocardial infarction, coro-
ary artery stenosis on coronary angiography, wall
otion abnormality on echocardiogram), previous
ardiac surgery (coronary artery bypass grafting or
eart valve replacement), chronic pulmonary dis-
ase, peripheral vascular disease, chronic renal fail-
re (serum creatinine 2.0 mg/dl), plasma B-type
atriuretic peptide (BNP) level, if it was obtained
ithin a month of echocardiography, history of a
erebrovascular accident, and physical activity level
activity level was classified as active if the patient
ived independently and limited if the patient re-
uired assisted care).
We also collected data concerning medical treat-
ent with aspirin, angiotensin-converting enzyme
nhibitors, or angiotensin receptor blockers, beta-
lockers, calcium channel blockers, diuretics, pe-B B R E V I A T I O N S
N D A C R O N YM S
S aortic stenosis
UC area under the curve
VR aortic valve replacem
NP B-type natriuretic
eptide
V left ventricular
VEF left ventricular ejectipheral vasodilators, and statins.
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901chocardiography. LV GEOMETRY AND SYSTOLIC
UNCTION. LV dimensions were acquired in the
arasternal long-axis view. LV internal dimension
nd posterior wall and septal thickness were mea-
ured at end-diastole and at end-systole (30). LV
ass was calculated with the corrected formula of
he American Society of Echocardiography and
ndexed for body surface area (30). LV end-diastolic
olume, end-systolic volume, and ejection fraction
ere calculated by Simpson’s method (30).
ORTIC STENOSIS SEVERITY. The Doppler echo-
ardiographic indexes of AS severity included the
eak Doppler velocity across the aortic valve, the
eak and mean transvalvular pressure gradient ob-
ained with the use of the modified Bernoulli
quation, and the aortic valve area obtained with
he use of the standard continuity equation (2).
V FILLING HEMODYNAMICS. Early transmitral fill-
ng peak velocity, early deceleration time, and trans-
itral atrial wave velocity were obtained with a
ulsed-wave sample at the tip of the mitral valve
31). Early diastolic velocity of the lateral aspect of
he mitral annulus (E=) was measured by Doppler
issue imaging (32). Pulmonary vein flow was ob-
ained on apical 4-chamber view. Abnormal pulmo-
Table 1. Comparison of Echocardiographic Variables Between N
N
LV geometry and systolic function
LVEF (%)* 121
Stroke volume (ml)* 109
LVID, diastolic (mm) 116
LVID, systolic (mm) 117
LV mass index 116
Aortic stenosis severity
Vmax (m/s) 124
Mean pressure gradient (mm Hg) 120
Aortic valve area (cm2) 120
Diastolic parameters
E (cm/s)* 117
A (cm/s) 97
E/A 101
Deceleration time (ms) 115
E= (cm/s) 122
E/E=* 122
E/E= 8 122
E/E= 15* 122
Abnormal pulmonary vein ﬂow 53
Systolic pulmonary artery pressure (mm Hg) 98
*p  0.05.
A  atrial; E  early; LV  left ventricular; LVEF  left ventricular ejection fractionary vein flow was determined as blunting or
eversal of the systolic component of the pulsed
oppler flow signal (31). As E/E= 15 and E/E=
8 usually indicate an elevated and normal LV
lling pressure respectively (31), we performed a
eparate analysis using these cutoff values.
ULMONARY ARTERY SYSTOLIC PRESSURE. Pulmo-
ary artery systolic pressure was estimated as the
um of the right ventricular to right atrial pressure
radient during systole and the right atrial pressure.
he right ventricular to right atrial peak systolic
ressure gradient was calculated by the modified
ernoulli equation. Right atrial pressure was esti-
ated based on echocardiographic characteristics of
he inferior vena cava (33).
linical outcome. The end point for the present
tudy was death within 1 year of follow-up. The last
valuation of patient survival status was performed
n May 2009.
tatistical analysis. All analyses were performed with
he statistical software program SPSS V.13.0 (SPSS
nc., Chicago, Illinois). Continuous data were pre-
ented as mean  SD. Categorical data were
resented as an absolute number or percentages.
he significance level was set at p  0.05.
urvivors and Survivors
Nonsurvivors
(n  47)
Survivors
(n  78) p Value
50 16 55 15 0.042
56 13 63 19 0.015
47 9 47.0 12 0.836
34 10 33 12 0.727
123 38 128 62 0.674
3.8 1.0 3.7 0.9 0.68
35 19 32 16 0.362
0.7 0.2 0.8 0.2 0.126
111 33.86 94.5 33.62 0.009
96 45 96 39 0.932
1.14 0.7 1.13 0.8 0.956
237 114 247 100 0.602
7.7 3.2 8.4 3.2 0.299
16.9 7.4 12.2 5.7 0.001
6% 19% 0.057
55% 20% 0.001
50% 42% 0.548
48 14 45 14 0.353ons; LVID  left ventricular internal dimension.
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902Between-groups comparisons of baseline data
ere performed using the independent-samples t
est. All categorical variables were compared be-
ween the 2 groups using the Pearson chi-square
est. Test of homogeneity of variances was per-
ormed for each individual variable with the Levene
tatistic.
Clinical and statistical variables were entered
nto Cox regression models to evaluate the inde-
Table 2. Comparison of Clinical Variables Between Nonsurvivor
Parameter N
Age (yrs)* 125
Male sex 125
Height (cm) 125
Weight (lbs) 125
Symptoms
Dyspnea 120
Angina 120
Syncope 120
Any symptoms 120
Cardiovascular risk factors
Smoking history 119
Hypertension 119
Diabetes mellitus* 118
Hyperlipidemia 119
Cardiovascular comorbidities
Congestive heart failure 120
Atrial ﬁbrillation 119
Coronary heart disease 119
Old myocardial infarction 118
Previous heart surgery 124
Peripheral vascular disease 119
History of cerebrovascular accident 119
Noncardiac comorbidities
Chronic renal failure 119
Chronic obstructive pulmonary disease 120
Inactive 119
Malignancy 118
Medications
Aspirin 119
ACE inhibitors/ARBs 119
Beta-blockers 119
Calcium channel blockers 119
Diuretics 119
Vasodilators 119
Statins 119
Laboratory
Serum creatinine 114
Serum BNP (pg/ml) 85
BNP 300 (pg/ml)* 85
*p  0.05.
ACE  angiotensin-converting enzyme; ARBs  angiotensin receptor blockers; BNendent predictors of 1-year survival. Hazard
atios were estimated using Cox proportional
azards models. Hazard ratios with 95% confi-
ence intervals were provided when appropriate.
aplan-Meier analysis was used to estimate sur-
ival. The log-rank test was used to compare
urvival across 2 groups. Data are presented as
ean  SD. A p value 0.05 was considered
tatistically significant.
d Survivors
Nonsurvivors
(n  78)
Survivors
(n  47) p Value
85 11 80 11 0.02
63% 61% 0.87
66 4 66 5 0.484
152 33 160 41 0.313
60% 53% 0.44
19% 22% 0.63
10% 12% 0.807
71% 63% 0.379
35% 36% 0.948
69% 76% 0.376
19% 40% 0.016
52% 51% 0.878
60% 43% 0.056
40% 27% 0.133
54% 47% 0.417
13% 16% 0.624
17% 13% 0.61
21% 12% 0.186
21% 12% 0.186
21% 19% 0.767
21% 15% 0.358
17% 11% 0.556
17% 19% 0.818
33% 36% 0.762
44% 51% 0.459
40% 43% 0.735
19% 23% 0.604
42% 41% 0.971
25% 25% 0.967
52% 44% 0.381
1.45 0.85 1.38 1.04 0.715
1,345 1,550 950 1,140 0.198
84% 65% 0.048s anP  B-type natriuretic peptide.
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903E S U L T S
here were 54 (43%) men and 71 (57%) women
ith a mean age of 81.6  11 years. Clinical
ariables were available for all patients. The LVEF
as calculated using Simpson’s rule in 74% of cases.
n all other cases, LVEF was estimated visually by
experienced echocardiographers (S.B. and R.J.S).
reliable continuous waveform signal of TR for
stimation of systolic pulmonary artery pressure was
resent in 98 (78%) patients. The atrial wave of
itral inflow pulsed-wave Doppler signal was re-
orded in 117 (94%) of cases. Mitral annulus tissue
oppler imaging was available for 122 (98%), and
ulmonary vein flow was interpretable in 53 (42%)
atients (Table 1). The BNP level was measured in
5 (68%) of patients (Table 2).
The mean aortic valve area was 0.72  0.12 cm2,
he peak velocity across the aortic valve was 3.8 
.9 m/s, and the mean pressure gradient was 33 
7 mm Hg. The reasons that AVR was not per-
ormed are shown in Table 3.
omparison of clinical and echocardiographic parame-
ers between survivors and nonsurvivors. The overall
-year rate survival was 62.4%. As shown in Table
, univariate analysis demonstrated that survivors
ompared with nonsurvivors were younger (80.0 
0.9 years vs. 84.9  11.1 years, p  0.02), and a
istory of diabetes was more prevalent in survivors
ompared with nonsurvivors (40% vs. 19%, p 
.016). There was no significant difference in the
revalence of any of the symptoms attributable to
S between the 2 study groups (71% vs. 63%, p 
.379). In addition, there was no difference with
Table 3. Reasons That Aortic Valve Replacement Was
Not Performed
Asymptomatic patients (no.) 41
Noncardiac comorbidities 17 (41%)
Asymptomatic status 15 (36%)
Advanced age 6 (15%)
Patient declined intervention 3 (8%)
Symptomatic patients (no.) 79
Cardiac comorbidities 12 (15%)
Noncardiac comorbidities 28 (36%)
Advanced age 11 (14%)
Symptoms thought due to another etiology 8 (10%)
Patient declined intervention 5 (6%)
Referred to percutaneous aortic valve replacement 4 (5%)
Died before surgery 10 (13%)
No data regarding symptoms 5
Most prevalent reason for nonreferral to surgical aortic valve replacement waspcomorbidities in both asymptomatic and symptomatic cohorts.egard to the distribution of other cardiovascular
iseases, noncardiac comorbidities, and medical
reatment. Although the mean plasma BNP levels
ere higher in nonsurvivors compared with survi-
ors, this difference did not reach statistical signif-
cance (1,345 1,550 vs. 950 1,140, p 0.198).
owever, the BNP cutoff value of 300 pg/ml was
ignificantly more prevalent in nonsurvivors com-
ared with survivors (84% vs. 65%, p  0.048).
As shown in Table 1, survivors compared with
onsurvivors had a greater LVEF (55 15 vs. 50
6, p  0.042), a higher LV stroke volume (63 
9 ml vs. 56  13 ml, p  0.015), a lower E/E=
atio (12.19  5.7 vs. 16.87  7.43, p  0.001),
nd a lower prevalence of E/E= 15 (20% vs. 55%,
 0.001). The rest of the echocardiographic
ariables of LV geometry, AS severity, and diastolic
arameters were also similar between the 2 study
roups. Figure 1 shows the receiver-operator char-
cteristic curve for the prediction of prognosis in
noperated severe AS. The areas under curve
AUC) and corresponding p values for the 1-year
ortality rate are shown for E/E=, LVEF, and
NP level. E/E= was a significant predictor of
utcome (AUC  0.71 [0.62–0.81], p  0.001).
he baseline LVEF was significant for predicting
-year morality (AUC  0.61 [0.50–0.71], p 
.049), whereas the serum BNP level alone was an
nsignificant predictor (AUC  0.58 [0.46–0.70],
Se
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Figure 1. Receiver-Operator Characteristic Curve for the Predict
Prognosis in Unoperated Severe Aortic Stenosis
The area under the curve (AUC) and corresponding p values for the
mortality rate are shown for E/E=, left ventricular ejection fraction (L
and B-type natriuretic peptide (BNP).0.001)
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 p=0.199)
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904As shown in Figure 2, in patients with E/E=15
n  41), the 1-year survival rate was 40%, whereas
atients with E/E=15 (n 78) had a significantly
igher survival rate in the same time period (73.3%,
 0.0001). In symptomatic patients, the subgroup
f subjects with E/E= 15 (n  47), the 1-year
urvival rate was 72.3%, whereas in those with E/E=
15 (n  32) the 1-year survival rate was 37.5%
p  0.001). In asymptomatic patients with E/E=
15 (n  30) and E/E= 15 (n  9), the 1-year
urvival rate was 73.3% and 33.3%, respectively
p  0.029). Although E/E= 8 is usually a marker
f low ventricular filling pressure, there was no
ignificant difference in our study using this cutoff.
To determine whether this effect was due to
bnormal LV systolic function, we analyzed pa-
ients with preserved (LVEF50%) and those with
educed (LVEF 50%) LV systolic function sepa-
ately (Fig. 3). In patients with LVEF 50%, the
ubgroup with E/E= 15 (n  61) compared with
ubgroup with E/E= 15 (n  23) had a signifi-
antly better 1-year survival rate (73.8% vs. 47.8%,
 0.027). The benefit was even more prominent
n patients with LVEF 50%. The patients with
/E= 15 (n  17) and patients with E/E= 15
n  18) demonstrated a 70.6% and 22.3% 1-year
urvival rate, respectively (p  0.003).
As the plasma BNP level 300 pg/ml emerged
s a significant univariate predictor of 1-year mor-
ality, we further stratified the study population
sing a combination of E/E= and BNP level. In
Figure 2. One-Year Survival in Unoperated Severe Aortic Stenos
E/E= Cutoff of 15
There was signiﬁcantly higher 1-year survival rate in patients with E
asymptomatic (n  39) (A) and symptomatic (n  79) (B) subjectsatients with both E/E= 15 and BNP 300 ig/ml, there was a 75% (21 of 28) 1-year mortality
ate compared with a rate of 29% (16 of 56) in those
ithout this combination (p 0.0001). In contrast,
here was a 21% (4 of 21) 1-year mortality rate in
atients with E/E= 15 and BNP 300 ng/ml
ompared with a 50% (33 of 65) mortality rate in
atients without this combination (p  0.02).
To account for multiple confounders, we created
ox regression models. Adjustments were made for
ll significant univariate variables as well as all
linical variables that had potential impact on
-year survival. As shown in Table 4, the significant
redictors of mortality in these models were E/E=
15 with a relative risk of 2.34 (1.27–4.33, p 
.0072) and a combination of E/E= 15 and BNP
300 ng/ml with a relative risk of 2.59 (1.21–5.55,
 0.014).
I S C U S S I O N
V systolic function is a major prognostic marker
or valvular heart disease. Currently, an LVEF
50% is used as an American Heart Association/
merican College of Cardiology guideline for rec-
mmending AVR in asymptomatic patients (2).
owever, in our study we found that E/E= was
ore prognostic than LVEF. The findings of our
tudy are not completely unexpected. In patients
ith severe AS, obstruction of LV outflow results in
ystolic pressure overload and LV wall hypertrophy.
s a result of increased wall thickness and dimin-
atients With and Without Symptoms as Stratiﬁed by
15 compared with patients with E/E= 15 among both
0.029). Cum  cumulative.is P
/E=shed compliance of the chamber, LV end-diastolic
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905ressure increases without chamber dilation (34–36).
hus, increased end-diastolic pressure usually reflects
iastolic rather than systolic dysfunction (37). Dia-
tolic dysfunction is prevalent in patients with pre-
erved systolic ejection performance and is very fre-
uent in patients with depressed systolic function
38,39). The Doppler-derived E/E= ratio has been
ound to be a reliable estimate of LV filling pressure in
atients with AS (40). Our study demonstrates that an
levated E/E= ratio is a marker for a subset of patients
ith AS at a very high risk of 1-year mortality.
Assessment of symptoms is subjective and is
ften difficult in the elderly, particularly in inactive
ubjects. Symptoms develop in 10% to 40% of
symptomatic AS patients on an exercise stress test
t a relatively low workload (22–27). In our series,
n asymptomatic status was not associated with
etter survival. The absence of symptoms was also
n unreliable indicator of marked echocardio-
raphic changes, such as a low LVEF and pulmo-
ary hypertension associated with severe AS. Of
ote, we found that 12% of asymptomatic patients
ad both an LVEF 40% and pulmonary artery
ypertension (estimated pulmonary artery pressure
35 mm Hg). In patients with severe AS and
ncertainty with regard to asymptomatic status,
xercise stress testing is useful to identify occult
ymptoms as well as for risk stratification (41).
owever, given the advanced age and clinical char-
Figure 3. One-Year Survival in Unoperated Severe Aortic Stenos
E/E= Cutoff of 15
One-year survival in unoperated severe AS patients with LVEF 50%
There was signiﬁcantly higher 1-year survival rate in patients with E
with LVEF 50% (n  84) (A) and subjects with LVEF ejection fractcteristics of our study population, stress testingay not have been feasible in the majority of
articipants. For patients who are unable to exer-
ise, E/E= seems to be a valuable echo-Doppler
arameter for risk stratification.
In patients with AS, plasma BNP levels have
een demonstrated to be correlated with LV end-
ystolic wall stress and to predict the onset of
ymptoms (42–44). The mean plasma BNP level in
ur cohort was considerably higher compared with
atients With LVEF >50% and LVEF <50% as Stratiﬁed by
 35) and LVEF 50% (n  84) as stratiﬁed by E/E= cutoff of 15.
15 compared with patients with E/E= 15 among both subjects
50% (B). Abbreviations as in Figures 1 and 2.
Table 4. Cox Regression Model Using Variables Signiﬁcant in U
and Clinically Signiﬁcant Variables
Parameter Relative Risk 95% Conﬁdenc
Model 1 (N  110)
Age 1.02 0.98–1.
LVEF 50% 0.56 0.31–1.
E/E= 15* 2.34 1.27–4.
Presence of symptoms 1.01 0.54–1.
Model 2 (N  78)
Age 1.02 0.97–1.
LVEF 50% 0.68 0.32–1.
E/E= 15* 2.48 1.15–5.
BNP 300 ng/ml 1.48 0.57–3.
Presence of symptoms 0.93 0.46–1.
Model 3 (N  79)
Age 1.02 0.98–1.
LVEF 50% 0.67 0.32–1.
E/E= 15 and BNP 300 ng/ml* 2.59 1.21–5.
*p  0.05.is P
(n
/E=nivariate Analysis
e Interval p Value
05 0.328
02 0.057
33 0.007
91 0.966
07 0.521
44 0.313
38 0.021
87 0.424
92 0.852
08 0.325
39 0.278
55 0.014Abbreviations as in Tables 1 and 2.
v
d
o
c
w
l
l
l
H
n
d
e
r
s
E
d
s
s
d
a
a
v
D
t
s
fi
c
h
s
c
t
r
u
w
S
s
a
n
v
i
t
o
C
T
p
p
a
E
r
v
L
a
t
p
R
D
M
R
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 9 , 2 0 1 0
S E P T E M B E R 2 0 1 0 : 8 9 9 – 9 0 7
Biner et al.
Prognostic Value of E/E= in Aortic Stenosis
906alues observed in asymptomatic AS (43,44). This
ifference is probably due to different characteristics
f our study population. Our cohort primarily
onsisted of symptomatic AS patients or patients
ith an unclear symptomatic status due to physical
imitations. The predictive value of plasma BNP
evel cutoffs, useful in truly asymptomatic AS, had a
imited role in risk stratification in our cohort.
owever, the combined use of plasma BNP 300
g/ml and E/E= 15 was the most accurate pre-
ictor for identifying a subset of patients with an
xtremely poor outcome and a high 1-year mortality
ate of 75%.
Recently, Mullens et al. (45) failed to demon-
trate a correlation between filling pressures and
/E= ratio in patients with primary LV systolic
ysfunction and considerable LV dilation. Our
tudy cohort consisted mostly of patients with
evere AS and concentric LV hypertrophy, but LV
imensions and LVEF were normal or slightly
bnormal in the majority of cases. In patients with
depressed LVEF, the first-line evidence of ele-
ated LV filling pressure is derived from the
oppler mitral inflow pattern. However, in pa-
ients with a normal LVEF, E/E= 15 is con-
idered to be a reliable marker of high left-sided
lling pressures (31).
Unoperated AS patients are subject to both
ardiac and noncardiac mortality. Subjects with a
igh perioperative risk are increasingly being con-
idered for percutaneous AVR. Patients with a highThoracic Surgeons. J Am Coll Cardiol
2008;52:e1–142. al. A new method oomorbidity profile are likely to benefit most from
his new endovascular approach to AVR. In this
egard, we found that elevated E/E= may serve as a
seful echo-Doppler parameter to identify patients
ith increased cardiac risk.
tudy limitations. The retrospective nature of this
tudy and the modest number of patients evaluated
re limitations of the study. In addition to the small
umber of patients, hemodynamic and laboratory
ariables were obtained at different times; hence, it
s possible that there were different loading condi-
ions and filling pressures at the time of echocardi-
graphy and during measurement of the BNP.
O N C L U S I O N S
he overall prognosis of unoperated severe AS is
oor. In patients with severe AS, E/E= has inde-
endent prognostic value. Among multiple clinical
nd echocardiographic parameters, we found that
/E= 15 is the single most accurate parameter for
isk stratification. In patients with unoperated se-
ere AS, E/E= 15 is superior to age, reduced
VEF, or plasma BNP levels in identifying subjects
t very high risk of dying within 1 year. However,
he combination of E/E= and BNP is even more
redictive of the 1-year prognosis.
eprint requests and correspondence: Dr. Robert J. Siegel,
ivision of Cardiology/Heart Institute, Cedars-Sinai
edical Center, 8700 Beverly Blvd., Room 5623, Loscardiac risk and a relatively favorable noncardiac Angeles, California 90048. E-mail: siegel@cshs.org.1
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